ADHDPhase 3NCT00228540
Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD
A Phase 3 study testing Modafinil in people with ADHD, run by Cephalon at 39 sites in United States.
Trial summary
An 8-week, Open-Label Study to Characterize the Response to Modafinil (85mg Film-Coated Tablet) Treatment at Dosages up to 425mg/Day in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) (With an Open-Ended Extension Period) Read more about this study
- Who is it for?
- Ages 6 to 17 years
- Conditions the study is for
- ADHD
- What is being tested?
- Modafinil
- How many people
- Not given
- Where
- 39 sitesUnited States
- Study dates
- Sep 2005to Sep 2006
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Patients are included in the study if all of the following criteria are met:
- Written informed consent/assent is obtained.
- The patient is a boy or girl 6 through 17 years of age (inclusive) at the screening visit, and both the patient and parent/legal guardian are English-speaking.
- The patient has a previous diagnosis of ADHD and is currently receiving medication for the treatment of ADHD.
- The patient, or the patient's parent/legal guardian, is dissatified (VAS score <50) with current ADHD medication (medication and reason for dissatisfaction documented).
- The patient is in good health as determined by a medical or psychiatric history, screening physical examination, and clinical laboratory evaluations.
- Girls who are postmenarche or sexually active, must have a negative urine pregnancy test prior to the baseline visit, must be using a medically acceptable method of birth control, and must agree to continue use of this method for the duration of the study (and for 30 days after participation in the study). Acceptable methods of birth control include the following: barrier method with spermicide; steroidal contraceptive (eg, oral, transdermal, implant, or injected) in conjunction with a barrier method; intrauterine device (IUD); and abstinence.
- The patient's parent/legal guardian must be willing and able to comply with study procedures and restrictions.
Who cannot join
- Patients are excluded from participating in this study if 1 or more of the following criteria are met:
- The patient has any current psychiatric comorbidity, including but not limited to depression or other mood disorder, or pervasive mental disorder, that requires pharmacotherapy.
- The patient is satisfied with current ADHD medication and has no side effects.
- The patient is using other prescription medications for ADHD with psychoactive properties (eg, amphetamine, dextroamphetamine, methylphenidate, pemoline, atomoxetine) after the baseline visit.
- The patient has used monoamine oxidase (MAO) inhibitors within 1 week before the baseline visit.
- The patient has used an investigational drug within 1 month before the screening visit.
- The patient has a known clinically significant drug sensitivity to modafinil or any of its inactive ingredients.
- The patient is pregnant or lactating. (Any patients becoming pregnant during the study will be withdrawn from study).
Trial locations and contacts
39 sites in 1 country.
39 sites in 1 country
United States39 sites
Claghorn-Lesem Research
Bellaire, Texas, 77401
Odyssey Research
Bismarck, North Dakota, 58501
The Clinical Study Ceneter
Burlington, Vermont, 05401
Massachusetts General Hospital
Cambridge, Massachusetts, 02138
Medical University of SC
Charleston, South Carolina, 29425
Bancroft Clinical Research
Cherry Hill, New Jersey, 08034
Cincinnati Children's Hospital
Cincinnati, Ohio, 45229
Odyssey Research
Dearborn, Michigan, 48126
Prairie at Saint John's
Fargo, North Dakota, 58104
Hunterdon Pediatric Associates
Flemington, New Jersey, 08822
Hurley Medical Center
Flint, Michigan, 48503
Sarkis Clinical Trials
Gainesville, Florida, 32607
UCI Child Development Center
Irvine, California, 92612
Clinical Neuroscience Solution
Jacksonville, Florida, 32216
ProMed HealthCare
Kalamazoo, Michigan, 49008
Eastside Therapeutic Resource
Kirkland, Washington, 98033
Michael J. Rieser, MD
Lexington, Kentucky, 40509
Northwest Behavioral Research
Marietta, Georgia, 30060
Loyola University Medical Center Department of Psychiatry
Maywood, Illinois, 60153
Odyssey Research
McCook, Nebraska, 69001
UT Medical Group
Memphis, Tennessee, 38105
Clinical Neuroscience Solution
Memphis, Tennessee, 38119
Dominion Clinical Research
Midlothian, Virginia, 23112
Odyssey Research
Minot, North Dakota, 58701
Louisiana Research Associates
New Orleans, Louisiana, 70114
HALP Clinic and ADHD Research
Northbrook, Illinois, 60062
Pharmacology Research Institut
Northridge, California, 91324
University of Nebraska
Omaha, Nebraska, 68198-7630
Clinical Neurosciences
Orlando, Florida, 32806
Pedia Research, LLC
Owensboro, Kentucky, 42301
Regions Hospital
Saint Paul, Minnesota, 55101
OCCI, Inc Salem
Salem, Oregon, 97301
Pacific Sleep Medicine Service
San Diego, California, 92121
Melmed Center
Scottsdale, Arizona, 85254
Psycopharmacology Research - LSU Health Science Center
Shreveport, Louisiana, 71103
Advanced Pediatrics
Vienna, Virginia, 22180
Laszlo J. Mate, MD, PA
West Palm Beach, Florida, 33407
Cientifica, Inc.
Wichita, Kansas, 67207
Pediatrics and Adolescent
Woodstock, Georgia, 30189
About this study
Official title: An 8 Week, Open-Label Study to Characterize the Response to Modafinil (85 mg Film Coated Tablet) Treatment at Dosages Up to 425 mg/Day in Children and Adolescents With Attention Deficit/Hyperactivity Disorder (ADHD) (With an Open Ended Extension Period)
An 8-week, Open-Label Study to Characterize the Response to Modafinil (85mg Film-Coated Tablet) Treatment at Dosages up to 425mg/Day in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) (With an Open-Ended Extension Period)
- Conditions
- ADHD
- Being tested
- Modafinil
- Medical subject headings
- Attention Deficit Disorder with Hyperactivity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ModafinilDrug
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Sep 2005 (estimated)
- Study startSep 2005
- Study completionSep 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ADHDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Factorial
- Masking
- None (open label)
Sponsor and investigators
- Lead sponsor
- Cephalon
- Sponsor type
- Industry (pharma, biotech, devices)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00228540
- Sponsor's protocol ID
- C1538/3044/AD/US
- Status last verified
- May 2014
- First submitted
- 27 Sep 2005
- Last updated
- 9 May 2014
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 May 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An 8 Week, Open-Label Study to Characterize the Response to Modafinil (85 mg Film Coated Tablet) Treatment at Dosages Up to 425 mg/Day in Children and Adolescents With Attention Deficit/Hyperactivity Disorder (ADHD) (With an Open Ended Extension Period)
- ClinicalTrials.gov ID
- NCT00228540
- Acronym / sponsor ID
- C1538/3044/AD/US
- Conditions
- ADHD
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Lead sponsor
- CephalonIndustry (pharma, biotech, devices)
- Study start
- Sep 2005
- Study completion
- Sep 2006 (actual)
- First posted
- 29 Sep 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
An 8-week, Open-Label Study to Characterize the Response to Modafinil (85mg Film-Coated Tablet) Treatment at Dosages up to 425mg/Day in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) (With an Open-Ended Extension Period)
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Factorial
- Masking
- None (open label)
Who may qualify
- Ages
- 6 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (8 listed)
- Written informed consent/assent is obtained.
- The patient is a boy or girl 6 through 17 years of age (inclusive) at the screening visit, and both the patient and parent/legal guardian are English-speaking.
- The patient has a previous diagnosis of ADHD and is currently receiving medication for the treatment of ADHD.
- The patient, or the patient's parent/legal guardian, is dissatified (VAS score <50) with current ADHD medication (medication and reason for dissatisfaction documented).
- The patient is in good health as determined by a medical or psychiatric history, screening physical examination, and clinical laboratory evaluations.
Key exclusion criteria (8 listed)
- Patients are excluded from participating in this study if 1 or more of the following criteria are met:
- The patient has any current psychiatric comorbidity, including but not limited to depression or other mood disorder, or pervasive mental disorder, that requires pharmacotherapy.
- The patient is satisfied with current ADHD medication and has no side effects.
- The patient is using other prescription medications for ADHD with psychoactive properties (eg, amphetamine, dextroamphetamine, methylphenidate, pemoline, atomoxetine) after the baseline visit.
- The patient has used monoamine oxidase (MAO) inhibitors within 1 week before the baseline visit.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Modafinil | Drug | – |
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 May 2014.
Related trials for ADHD
Enrolling by invitationPhase 3
An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD
ADHD
Not yet recruitingPhase 2
Lisdexamfetamine For the Treatment of Conduct Disorder in Children
Conduct Disorder
RecruitingObservational study
Augmenting Parent Management Training for Child Temper Outbursts Using a Digital Tool
Disruptive Behavior Disorders, Conduct Disorder
Recruiting
Micronutrient Supplementation and Chronotherapy in Children With ADHD
Attention Deficit Hyperactivity Disorder (ADHD)
RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
ADHD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
39 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Modafinil in people with ADHD, run by Cephalon at 39 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 May 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 39 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 May 2014.